Risk factors for acquisition and mortality of multidrug-resistant Acinetobacter baumannii bacteremia A retrospective study from a Chinese hospital

被引:65
作者
Zhou, Hua [1 ]
Yao, Yake [1 ]
Zhu, Bingquan [2 ]
Ren, Danhong [3 ]
Yang, Qing [4 ]
Fu, Yiqi [1 ]
Yu, Yunsong [5 ]
Zhou, Jianying [1 ]
机构
[1] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Resp Dis, Hangzhou, Zhejiang, Peoples R China
[2] Zhejiang Univ, Childrens Hosp, Dept Child Hlth Care, Hangzhou, Zhejiang, Peoples R China
[3] Hangzhou Red Cross Hosp, Dept Crit Care Med, Hangzhou, Zhejiang, Peoples R China
[4] First Affiliated Hosp Coll Med, Collaborat Innovat Ctr Diag & Treatment Infect Di, State Key Lab Diagnost & Treatment Infect Dis, Hangzhou, Zhejiang, Peoples R China
[5] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Infect Dis, Hangzhou, Zhejiang, Peoples R China
关键词
Acinetobacter baumannii; bacteremia; MDRAB; multidrug-resistant; risk factors; BLOOD-STREAM INFECTION; GRAM-NEGATIVE BACTEREMIA; CARBAPENEM-RESISTANT; EPIDEMIOLOGY; COMBINATION; SULBACTAM; OUTCOMES; IMPACT; COLONIZATION; DEFINITIONS;
D O I
10.1097/MD.0000000000014937
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Bloodstream infection caused by Acinetobacter baumannii has become a major clinical concern, especially multidrug-resistant A baumannii (MDRAB). The aim of this study was to identify the risk factors of nosocomial acquired MDRAB bacteremia and to determine the risk factors related to the mortality of patients with MDRAB bacteremia. Patients with nosocomial acquired A baumannii bacteremia were enrolled between January, 2013 and December, 2017 at the First Affiliated Hospital, School of Medicine, Zhejiang University. Medical records were reviewed, and the clinical and microbial characteristics were collected. Among the 338 patients suffering from A baumannii bacteremia, 274 patients were infected with MDRAB bacteremia. Bacteremia-related mortality was 46.4% for the overall sample; 56.2% for MDRAB bacteremia patients, 4.7% for non-MDRAB bacteremia patients. The identified risk factors for developing MDRAB bacteremia were previous exposure to carbapenems [odds ratio (OR) 5.78, P=.005] and penicillins+ b-lactamase inhibitors (OR 4.29, P=.009). Primary bacteremia tended to develop non-MDR bacteremia (OR 0.10, P=.002). The risk factors for MDRAB bacteremia-related mortality were old age (OR 1.02, P=.036), a high Pitt bacteremia score (OR 1.32, P<.001), bacteremia occurring after severe pneumonia (OR 8.66, P<.001), while catheter-related infection (OR 0.47, P=.049) and operations for treating infection (OR 0.51, P=.043) may have a better outcome. Patients with MDRAB had a higher mortality rate. Patients with previous carbapenems and penicillins+ b-lactamase inhibitor exposure are at an increased risk of MDRAB bacteremia, whereas patients with primary bacteremia tended to develop non-MDR bacteremia. The risk factors for MDRAB bacteremia-related mortality were old age, a high Pitt bacteremia score, and bacteremia occurring after severe pneumonia, whereas catheter-related infection and operations for the treatment of infection may have a better outcome.
引用
收藏
页数:7
相关论文
共 45 条
[31]   Factors influencing survival in patients with multi-drug-resistant Acinetobacter bacteraemia [J].
Metan, Gokhan ;
Sariguzel, Fatma ;
Sumerkan, Bulent .
EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2009, 20 (05) :540-544
[32]   Treatment of Acinetobacter infections [J].
Michalopoulos, Argyris ;
Falagas, Matthew E. .
EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (05) :779-788
[33]   Changes in MIC Within a Global Collection of Acinetobacter baumannii Collected as Part of the Tigecycline Evaluation and Surveillance Trial, 2004 to 2009 [J].
Morfin-Otero, Rayo ;
Dowzicky, Michael J. .
CLINICAL THERAPEUTICS, 2012, 34 (01) :101-112
[34]   A Multicenter Case-Case Control Study for Risk Factors and Outcomes of Extensively Drug-Resistant Acinetobacter baumannii Bacteremia [J].
Ng, Tat Ming ;
Teng, Christine B. ;
Lye, David C. ;
Apisarnthanarak, Anucha .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2014, 35 (01) :49-55
[35]   In vitro effects of tigecycline in combination with colistin (polymyxin E) and sulbactam against multidrug-resistant Acinetobacter baumannii [J].
Ni, Wentao ;
Cui, Junchang ;
Liang, Beibei ;
Cai, Yun ;
Bai, Nan ;
Cai, Xuejiu ;
Wang, Rui .
JOURNAL OF ANTIBIOTICS, 2013, 66 (12) :705-708
[36]   A case-control study to identify predictors of 14-day mortality following carbapenem-resistant Acinetobacter baumannii bacteraemia [J].
Nutman, A. ;
Glick, R. ;
Temkin, E. ;
Hoshen, M. ;
Edgar, R. ;
Braun, T. ;
Carmeli, Y. .
CLINICAL MICROBIOLOGY AND INFECTION, 2014, 20 (12) :O1028-O1034
[37]  
O'Grady NP, 2011, CLIN INFECT DIS, V52, pE162, DOI [10.1093/cid/cir257, 10.1016/j.ajic.2011.01.003]
[38]   Summer Peaks in the Incidences of Gram-Negative Bacterial Infection Among Hospitalized Patients [J].
Perencevich, Eli N. ;
McGregor, Jessina C. ;
Shardell, Michelle ;
Furuno, Jon P. ;
Harris, Anthony D. ;
Morris, J. Glenn, Jr. ;
Fisman, David N. ;
Johnson, Judith A. .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2008, 29 (12) :1124-1131
[39]   Seasonality in Gram-negative and healthcare-associated infections [J].
Richet, H. .
CLINICAL MICROBIOLOGY AND INFECTION, 2012, 18 (10) :934-940
[40]   Acinetobacter baumannii bacteremia:: Clinical and prognostic features [J].
Rodríguez-Baño, J ;
Pascual, A ;
Gálvez, J ;
Muniain, MA ;
Ríos, MJ ;
Martínez-Martínez, L ;
Pérez-Cano, R ;
Perea, EJ .
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2003, 21 (05) :242-247